Mullen L, Seavill M, Hammouz R, Bottazzi B, Chan P, Vaudry D et al. Development of ‘Redox Arrays’ for identifying novel glutathionylated proteins in the secretome. Sci Rep. 2015;5:14630.
Mullen L, Chamberlain G, Sacre S. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res Ther. 2015;17(1).
Salzano S, Checconi P, Hanschmann E, Lillig C, Bowler L, Chan P et al. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proceedings of the National Academy of Sciences. 2014;111(33):12157-12162.
Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J et al. Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. Expert Opinion on Drug Delivery. 2014;11(1):5-16.
Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G et al. Latent cytokines for targeted therapy of inflammatory disorders. Expert Opinion on Drug Delivery. 2014;11(1):101-110.
Koutsokeras A, Purkayastha N, Rigby A, Subang M, Sclanders M, Vessillier S et al. Generation of an efficiently secreted, cell penetrating NF-κB inhibitor. The FASEB Journal. 2013;28(1):373-381.
Mullen L, Adams G, Foster J, Vessillier S, Koster M, Hauser H et al. A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints. Annals of the Rheumatic Diseases. 2013;73(9):1728-1736.
Mullen L, Adams G, Chernajovsky Y. Increased disulphide dimer formation of latent associated peptide fusions of TGF-β by addition of l-cystine. Journal of Biotechnology. 2012;161(3):269-277.